📣 VC round data is live. Check it out!

Delcath Systems Valuation Multiples

Discover revenue and EBITDA valuation multiples for Delcath Systems and similar public comparables like Standard BioTools, Myriad Genetics, IVF hartmann, ClearPoint Neuro and more.

Delcath Systems Overview

About Delcath Systems

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.


Founded

1988

HQ

United States

Employees

96

Financials (LTM)

Revenue: $92M
EBITDA: $17M

EV

$303M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Delcath Systems Financials

Delcath Systems reported last 12-month revenue of $92M and EBITDA of $17M.

In the same LTM period, Delcath Systems generated $79M in gross profit, $17M in EBITDA, and had net loss of ($6M).

Revenue (LTM)


Delcath Systems P&L

In the most recent fiscal year, Delcath Systems reported revenue of $85M and EBITDA of $25M.

Delcath Systems is profitable as of last fiscal year, with gross margin of 86%, EBITDA margin of 29%, and net margin of 3%.

See analyst estimates for Delcath Systems
LTMLast FY202320242025202620272028
Revenue$92M$85M$2M$37M$85M
Gross Profit$79M$73M$1M$31M$73M
Gross Margin86%86%69%83%86%
EBITDA$17M$25M($46M)($12M)$1M
EBITDA Margin19%29%(2233%)(33%)1%
EBIT Margin(9%)1%(1849%)(33%)1%
Net Profit($6M)$3M($48M)($26M)$3M
Net Margin(7%)3%(2309%)(71%)3%

Financial data powered by Morningstar, Inc.

Delcath Systems Stock Performance

Delcath Systems has current market cap of $391M, and enterprise value of $303M.

Market Cap Evolution


Delcath Systems' stock price is $11.34.

Delcath Systems share price increased by 9.2% in the last 30 days, and decreased by 30.0% in the last year.

Delcath Systems has an EPS (earnings per share) of $0.08.

See more trading valuation data for Delcath Systems
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$303M$391M2.6%9.2%27.4%-30.0%$0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Delcath Systems Valuation Multiples

Delcath Systems trades at 3.3x EV/Revenue multiple, and 17.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Delcath Systems

EV / Revenue (LTM)


Delcath Systems Financial Valuation Multiples

As of May 13, 2026, Delcath Systems has market cap of $391M and EV of $303M.

Delcath Systems has a P/E ratio of (62.7x).

LTMLast FY202320242025202620272028
EV/Revenue3.3x3.6x146.8x8.1x3.6x
EV/EBITDA17.6x12.1x(6.6x)(24.9x)n/m
EV/EBIT(38.0x)n/m(7.9x)(24.4x)n/m
EV/Gross Profit3.8x4.1x211.9x9.8x4.1x
P/E(62.7x)145.0x(8.2x)(14.8x)145.0x
EV/FCF18.8x13.4x(9.7x)(15.8x)14.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Delcath Systems Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Delcath Systems Margins & Growth Rates

Delcath Systems grew revenue by 22% but EBITDA decreased by 87% in the last fiscal year.

In the most recent fiscal year, Delcath Systems reported gross margin of 86%, EBITDA margin of 29%, and net margin of 3%.

See estimated margins and future growth rates for Delcath Systems

Delcath Systems Margins

Last FY202420252026202720282029
Gross Margin86%83%86%86%
EBITDA Margin29%(33%)1%3%
EBIT Margin1%(33%)1%(22%)
Net Margin3%(71%)3%(21%)
FCF Margin27%(52%)25%5%

Delcath Systems Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth22%1702%129%22%
Gross Profit Growth22%2069%137%22%
EBITDA Growth(87%)(74%)(108%)232%
EBIT Growth(3478%)(67%)(105%)(3595%)
Net Profit Growth(909%)(45%)(110%)(909%)
FCF Growth(79%)(39%)(209%)(78%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Delcath Systems Operational KPIs

Delcath Systems' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.8M for the same period.

Delcath Systems' Rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Delcath Systems' Rule of X is 58% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Delcath Systems
LTMLast FY202320242025202620272028
Rule of 4044%25%———
Bessemer Rule of X81%58%———
Revenue per Employee—$0.9M———
Opex per Employee—$0.8M———
S&M Expenses to Revenue0%0%——0%
G&A Expenses to Revenue56%51%——51%
R&D Expenses to Revenue41%34%848%37%34%
Opex to Revenue—85%1918%117%85%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Delcath Systems Competitors

Delcath Systems competitors include Standard BioTools, Myriad Genetics, IVF hartmann, ClearPoint Neuro, TaiDoc Technology, Coltene, Revenio Group, Advanced Technology Company, Medios and Universal Vision.

Most Delcath Systems public comparables operate across Medical Devices, HealthTech, DeepTech and BioTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Standard BioTools(0.4x)(0.4x)0.5x0.7x
Myriad Genetics0.6x0.6x12.1x12.2x
IVF hartmann1.2x—7.7x—
ClearPoint Neuro10.6x9.1x(25.7x)(25.1x)
TaiDoc Technology1.8x—4.0x—
Coltene1.3x1.3x11.1x10.8x
Revenio Group3.1x2.7x10.9x10.6x
Advanced Technology Company2.0x—154.5x—

This data is available for Pro users. Sign up to see all Delcath Systems competitors and their valuation data.

Start Free Trial

Delcath Systems Funding History

Before going public, Delcath Systems raised $35M in total equity funding, across 1 round.


Delcath Systems Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-16Undisclosed stage—$35M——

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Delcath Systems

When was Delcath Systems founded?Delcath Systems was founded in 1988.
Where is Delcath Systems headquartered?Delcath Systems is headquartered in United States.
How many employees does Delcath Systems have?As of today, Delcath Systems has over 96 employees.
Who is the CEO of Delcath Systems?Delcath Systems' CEO is Gerard J. Michel.
Is Delcath Systems publicly listed?Yes, Delcath Systems is a public company listed on Nasdaq.
What is the stock symbol of Delcath Systems?Delcath Systems trades under DCTH ticker.
When did Delcath Systems go public?Delcath Systems went public in 2000.
Who are competitors of Delcath Systems?Delcath Systems main competitors include Standard BioTools, Myriad Genetics, IVF hartmann, ClearPoint Neuro, TaiDoc Technology, Coltene, Revenio Group, Advanced Technology Company, Medios, Universal Vision.
What is the current market cap of Delcath Systems?Delcath Systems' current market cap is $391M.
What is the current revenue of Delcath Systems?Delcath Systems' last 12 months revenue is $92M.
What is the current revenue growth of Delcath Systems?Delcath Systems revenue growth (NTM/LTM) is 25%.
What is the current EV/Revenue multiple of Delcath Systems?Current revenue multiple of Delcath Systems is 3.3x.
Is Delcath Systems profitable?Yes, Delcath Systems is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Delcath Systems?Delcath Systems' last 12 months EBITDA is $17M.
What is Delcath Systems' EBITDA margin?Delcath Systems' last 12 months EBITDA margin is 19%.
What is the current EV/EBITDA multiple of Delcath Systems?Current EBITDA multiple of Delcath Systems is 17.6x.
What is the current FCF of Delcath Systems?Delcath Systems' last 12 months FCF is $16M.
What is Delcath Systems' FCF margin?Delcath Systems' last 12 months FCF margin is 18%.
What is the current EV/FCF multiple of Delcath Systems?Current FCF multiple of Delcath Systems is 18.8x.
How many companies Delcath Systems has acquired to date?Delcath Systems hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Delcath Systems has invested to date?Delcath Systems hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Delcath Systems

Lists including Delcath Systems

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial